
Novo Nordisk Plans 9,000 Job Cuts to Boost Profitability
Novo Nordisk is cutting 9,000 jobs and lowering its profit growth forecast due to increased competition and knockoff versions of its obesity drugs Ozempic and Wegovy, as part of a broader restructuring effort under new CEO Mike Doustdar to improve long-term positioning amid declining stock performance.












